News & media

CLL Advocates NZ Launches a New Zealand Patient Guide

CLL Advocates is pleased to announce the official launch of it's Guide for Patients in New Zealand.…

Continue reading

Dr. Davids on Factors to Inform Treatment Selection in CLL

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients…

Continue reading

The Role of Chemoimmunotherapy Dwindles Among New Regimens in Frontline CLL

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with…

Continue reading

CLL Advocates NZ Newsletter Issue 4

Welcome to issue 3 of the CLL Advocates newsletter. This month's newsletter focuses on research and…

Continue reading

Triple Therapy for CLL Shows Promise in Phase 2 Trial

Results from a phase 2 study of 3 oral targeted agents for chronic lymphocytic leukemia (CLL)…

Continue reading

The CLLANZ Inaugural CLL Seminar

Three top haematologists will present and take questions on CLL disease, diagnosis and management,…

Continue reading

Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors

Patients with CLL/small lymphocytic lymphoma (CLL/SLL) who had an MYD88 L265P mutation were…

Continue reading

Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia

CLL proliferate in secondary lymphatic organs where cancer cells engage in molecular and cellular…

Continue reading

Which Drug Therapy for CLL, Time-Limited or Continuous?

About two thirds of patients who are diagnosed with chronic lymphocytic leukemia (CLL) are…

Continue reading

EU approves Imbruvica plus rituximab in first-line CLL

There’s a growing recognition that some of the CAR-T shortfalls in CLL are due to an impaired…

Continue reading

4 October – CLL Treatments Today: What Should I Know?

Join us for a virtual town meeting for chronic lymphocytic leukemia (CLL) patients and family…

Continue reading

Clinical Trials Survey 2020

Please help Andrew give a powerful speech based on your experiences and thoughts around clinical…

Continue reading

Acalabrutinib Shows Promising Results for the Treatment of CLL

Jennifer Woyach, MD, discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib…

Continue reading

Online webinar: Telling Others About My CLL Diagnosis

How do you tell family and friends that you have leukemia? Chronic Lymphocytic Leukemia (CLL)…

Continue reading

Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?

There’s a growing recognition that some of the CAR-T shortfalls in CLL are due to an impaired…

Continue reading

World Leukemia Day – 4 September 2020

We are looking for people from all around the globe to participate in increasing the awareness of…

Continue reading

CLL Advocates NZ Newsletter Issue 3

Welcome to issue 3 of the CLL Advocates newsletter. This month's newsletter focuses on research and…

Continue reading

“Medical Cannabis: Knowledge, Attitudes and Expectations amongst NZ Health Care Professionals and their Patients”

The aim of the study is to find out what doctors and patients in New Zealand currently know about…

Continue reading

CLL Diagnosis Preceded by Decades of Increased Infection Susceptibility

Chronic lymphocytic leukemia (CLL) is well known for its close relationship with immune…

Continue reading

Burger Reviews BTK Inhibitors and Beyond in Frontline CLL

During a virtual Case Based Peer Perspectives event, Jan A. Burger, MD, PhD, discussed testing and…

Continue reading

Coutre Evaluates Treatment Options in Relapsed/Refractory CLL

During a virtual Case Based Peer Perspectives event, Steven Coutre, MD, reviewed a case of a…

Continue reading

COVID-19 Severity in CLL Correlates With 3 Disease Characteristics

The severity of coronavirus disease 2019 increases with age in patients with chronic lymphocytic…

Continue reading

Online webinar: Aggressive CLL Treatment Options: Are They Right for Me?

How do people living with CLL know when they may need a more aggressive treatment? Join us on…

Continue reading

Understanding Chronic Lymphocytic Leukemia

CURE speaks with Dr. Susan O'Brien, on behalf of the Leukemia and Lymphoma Society.

Continue reading

Ibrutinib May Improve CAR T-Cell Production for Patients With Chronic Lymphocytic Leukemia

Ibrutinib during CAR T-cell culture improved the yield and function of CAR T-cell products as…

Continue reading

TML Helps Predict Time to Treatment in CLL and its Precursor, Study Shows

Patients with chronic lymphocytic leukemia (CLL) often face months or years of uncertainty. A new…

Continue reading

Ball Score Predicts Benefit From Ibrutinib in CLL

The BALL score was able to identify a subset of patients with chronic lymphocytic leukemia (CLL)…

Continue reading

Cohen Expands on Treatment Options in Patients With Genomic Aberrations in CLL

During a virtual Case Based Peer Perspective event, Jonathon B. Cohen, MD, MS, , discussed a case…

Continue reading

FDA Clears clonoSEQ to Detect MRD in Chronic Lymphocytic Leukemia

ClonoSEQ, from Adaptive Biotechnologies, can detect 1 cancer cell among a million healthy cells.

Continue reading

Experts Outline Best Practices in the Treatment of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that can be treated to…

Continue reading